“The utility of a model-based cost-effectiveness analysis of degarelix versus leuprolide in the therapy of hormone-dependent advanced prostate cancer” (2013) Farmeconomia. Health economics and therapeutic pathways, 14(3), pp. 131–146. doi:10.7175/fe.v14i3.700.